Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Data at the Upcoming European Cancer Congress (ECCO-ESMO-ESTRO)

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

DUBLIN, Calif., June 20, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that updated clinical data from the dose escalation part of a randomized phase 1/2 clinical trial of subcutaneous SGI-110, a novel hypomethylating agent, in patients with relapsed/refractory acute myelogenous leukemia (r/r AML) will be presented in an oral session during the European Cancer Congress 2013 (ECCO-ESMO-ESTRO) in Amsterdam, Netherlands September 27 - October 1, 2013.

Help employers find you! Check out all the jobs and post your resume.

Back to news